Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NSCLC With EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableApproved For MarketingNCT01931306
What this trial is testing

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim
Testing effectiveness (Phase 2)Study completedNCT05263947
What this trial is testing

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Who this might be right for
Carcinoma, Non-Small-Cell LungBevacizumabTyrosine Kinase Inhibitor+1 more
Tianjin Medical University Cancer Institute and Hospital 35
Testing effectiveness (Phase 2)Ended earlyNCT01646125
What this trial is testing

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Who this might be right for
Advanced Non Small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals 59
Testing effectiveness (Phase 2)UnknownNCT05435274
What this trial is testing

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small-Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 380
Large-scale testing (Phase 3)UnknownNCT04500704
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 166
Large-scale testing (Phase 3)UnknownNCT04239833
What this trial is testing

SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd. 240
Early research (Phase 1)Study completedNCT01859026
What this trial is testing

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Who this might be right for
Lung CancerNon-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 43
Large-scale testing (Phase 3)Active Not RecruitingNCT07183189
What this trial is testing

SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 582
Large-scale testing (Phase 3)WithdrawnNCT03529084
What this trial is testing

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Who this might be right for
Carcinoma, Non-small Cell Lung
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Looking for participantsNCT06417814
What this trial is testing

Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Non-small Cell Lung Cancer
AstraZeneca 744
Large-scale testing (Phase 3)Active Not RecruitingNCT04923906
What this trial is testing

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 624
Testing effectiveness (Phase 2)Study completedNCT04790409
What this trial is testing

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Who this might be right for
Lung Cancer
Zhejiang Cancer Hospital 21
Large-scale testing (Phase 3)Ended earlyNCT02893332
What this trial is testing

Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)

Who this might be right for
Stage IV EGFR Mutated Non-Small Cell Lung Cancer
Sichuan Provincial People's Hospital 200
Not applicableUnknownNCT05513664
What this trial is testing

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon20 Insertion Mutations
Shanghai JMT-Bio Inc. 80
Early research (Phase 1)Ended earlyNCT02468661
What this trial is testing

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 23
Not applicableStudy completedNCT01785888
What this trial is testing

Europe-Japan Diagnostic Study for EGFR Testing

Who this might be right for
EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.
AstraZeneca 1,311
Testing effectiveness (Phase 2)Looking for participantsNCT06517953
What this trial is testing

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGFR G719XEGFR L861Q+1 more
Sun Yat-sen University 23
Testing effectiveness (Phase 2)Ended earlyNCT00988169
What this trial is testing

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 6
Early research (Phase 1)Ended earlyNCT04622072
What this trial is testing

XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Sihuan Pharmaceutical Holdings Group Ltd. 21
Early research (Phase 1)Ended earlyNCT06032936
What this trial is testing

BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations

Who this might be right for
NSCLC
LianBio LLC 4
Next Page